{
    "ticker": "KURA",
    "name": "Kura Oncology, Inc.",
    "description": "Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for the treatment of cancer. Founded in 2014 and headquartered in San Diego, California, Kura is dedicated to advancing its pipeline of drug candidates to improve outcomes for patients with cancer. The company's lead product candidate, tipifarnib, is an oral farnesyltransferase inhibitor being investigated for the treatment of various cancers, particularly those with specific genetic mutations. Kura is also developing other innovative therapies that target critical pathways in cancer biology, including the use of next-generation inhibitors that address mechanisms of resistance to existing therapies. With a team of experienced professionals in drug development and a commitment to scientific excellence, Kura Oncology strives to bring transformative therapies to patients, addressing unmet medical needs in oncology. The company\u2019s mission is to make a significant impact in the oncology space by leveraging cutting-edge research and development practices, while also fostering collaborations with academic and industry partners to accelerate the advancement of its programs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "https://www.kuraoncology.com",
    "ceo": "P. Jeffrey K. W. Kauffman",
    "social_media": {
        "twitter": "https://twitter.com/KuraOncology",
        "linkedin": "https://www.linkedin.com/company/kura-oncology"
    },
    "investor_relations": "https://investors.kuraoncology.com",
    "key_executives": [
        {
            "name": "P. Jeffrey K. W. Kauffman",
            "position": "CEO"
        },
        {
            "name": "Richard A. Heyman",
            "position": "President and COO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Development",
            "products": [
                "Tipifarnib"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kura Oncology, Inc. | Targeted Cancer Therapies",
        "meta_description": "Kura Oncology is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Learn more about our innovative pipeline and mission.",
        "keywords": [
            "Kura Oncology",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "Targeted Therapies",
            "Tipifarnib"
        ]
    },
    "faq": [
        {
            "question": "What is Kura Oncology known for?",
            "answer": "Kura Oncology is known for developing targeted therapies for the treatment of cancer, with a focus on its lead product candidate, tipifarnib."
        },
        {
            "question": "Who is the CEO of Kura Oncology?",
            "answer": "P. Jeffrey K. W. Kauffman is the CEO of Kura Oncology, Inc."
        },
        {
            "question": "Where is Kura Oncology headquartered?",
            "answer": "Kura Oncology is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Kura Oncology's main products?",
            "answer": "Kura Oncology's main product candidate is tipifarnib, which is being investigated for various cancers."
        },
        {
            "question": "When was Kura Oncology founded?",
            "answer": "Kura Oncology was founded in 2014."
        }
    ],
    "competitors": [
        "MRK",
        "BMY",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}